Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Articles

Pages

35403 items
1:01 PM, Sep 14, 2018  |  BC Week In Review | Company News  |  Deals

Fate gets license to Gladstone's stem cell tech

Fate Therapeutics Inc. (NASDAQ:FATE) obtained an exclusive license to IP from the Gladstone Institutes covering the generation of induced pluripotent stem cells (iPS cells) using CRISPR-mediated gene activation. Gladstone will receive $100,000 up front and...
12:15 PM, Sep 14, 2018  |  BC Week In Review | Company News  |  Deals

Oncolytics to conduct pilot study of oncolytic virus with SOLTI

Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY) partnered with the non-profit group SOLTI (Barcelona, Spain) to conduct a pilot study of the biotech's Reolysin pelareorep in the neoadjuvant setting for breast cancer. SOLTI will facilitate the trial,...
10:27 AM, Sep 14, 2018  |  BC Week In Review | Company News  |  Deals

Boehringer to acquire oncolytic virus company ViraTherapeutics

Boehringer Ingelheim GmbH (Ingelheim, Germany) exercised an option to acquire oncolytic virus company ViraTherapeutics GmbH (Innsbruck, Austria). Boehringer gained the option under a 2016 deal to jointly develop ViraTherapeutics' oncolytic virus therapy platform and its...
10:27 AM, Sep 14, 2018  |  BC Week In Review | Company News  |  Deals

Zai Lab gets Chinese rights to Novocure's oncology tech

Novocure Ltd. (NASDAQ:NVCR) granted Zai Lab Ltd. (NASDAQ:ZLAB) exclusive rights to oncology platform Tumor Treating Fields in China, including Hong Kong and Macau, and Taiwan. Novocure will receive $15 million up front and is eligible for...
10:26 AM, Sep 14, 2018  |  BC Week In Review | Company News  |  Deals

Boston Scientific to acquire Augmenix for $500M

Boston Scientific Corp. (NYSE:BSX) will acquire Augmenix Inc. (Waltham, Mass.) for $500 million in cash up front and up to $100 million in sales milestones. Boston Scientific will gain Augmenix's SpaceOAR hydrogel, which is used...
10:24 AM, Sep 14, 2018  |  BC Week In Review | Company News  |  Deals

Centre for the Commercialization of Antibiotics and Biologics and ImmunoBiochem partner for TNBC

The Centre for the Commercialization of Antibodies and Biologics (Toronto, Ontario) provided an undisclosed sum to ImmunoBiochem Corp. (Toronto, Ontario), which the biotech will use to develop IMB-212 which is in development to treat triple-negative...
8:18 AM, Sep 14, 2018  |  BC Week In Review | Company News  |  Deals

GNS, Amgen to use AI to explore patient response to mCRC drug Vectibix

GNS Healthcare Inc. (Cambridge, Mass), Amgen Inc. (NASDAQ:AMGN) and the Alliance for Clinical Trials in Oncology (Boston, Mass.) partnered to use artificial intelligence to identify factors that drive and predict patient responses to Amgen’s metastatic...
6:05 AM, Sep 14, 2018  |  BC Week In Review | Company News  |  Deals

Aurobino gains Novartis's U.S. dermatology and general U.S. oral solids portfolio

Novartis AG (NYSE:NVS; SIX:NOVN) said it will sell its Sandoz U.S. dermatology business and generic oral solids portfolio to Aurobindo Pharma Ltd. (NSE:AUROPHARMA; BSE:524804) for $900 million in cash. Novartis is also eligible for $100...
3:43 PM, Sep 13, 2018  |  BC Week In Review | Company News  |  Deals

Zealand brings in $205M for pipeline via royalty pharma deal

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will sell royalty rights and $85 million in potential commercial milestones tied to diabetes drugs Soliqua/Suliqua and Lyxumia/Adlyxin lixisenatide to Royalty Pharma (New York, N.Y.) for $205 million. Sanofi...
3:42 PM, Sep 13, 2018  |  BC Week In Review | Company News  |  Deals

Endocyte raises $175M

Endocyte Inc. (NASDAQ:ECYT) raised $175 million through the sale of 9.5 million shares at $18.50 in a follow-on underwritten by Jefferies, Wells Fargo, RBC Capital Markets and Wedbush. The price was a 2% discount to...

Pages